



## Gregory M. Heestand, MD

Clinical Associate Professor, Medicine - Oncology

### CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Center**

875 Blake Wilbur Dr

MC 6507

Stanford, CA 94305

Tel (650) 498-6000      Fax

### Bio

---

#### BIO

Dr. Heestand is a board-certified medical oncologist with a focus on gastrointestinal cancers, primarily hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer. He serves as the medical oncology champion of the Stanford Hepatobiliary Tumor Board, as well as the principal investigator of multiple clinical trials. He collaborates with campus laboratories to help develop new biomarker and treatment technologies. He is the former director of the Stanford Oncology Fellowship Program.

Dr. Heestand and his team take great pride in helping patients and their families face gastrointestinal cancer.

Outside of the clinic, Dr. Heestand enjoys playing the piano, teaching his kids about music, cooking for friends and family, and surfing the internet for interesting things to read.

#### CLINICAL FOCUS

- Hepatocellular Carcinoma
- Cholangiocarcinoma
- Gallbladder Cancer
- Gastrointestinal Cancers
- Medical Oncology

#### ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Medicine - Oncology
- Member, Stanford Cancer Institute

#### ADMINISTRATIVE APPOINTMENTS

- Hematology Oncology Fellowship Associate Director, Stanford University, (2022-2024)

- Oncology Fellowship Director, Stanford University, (2017-2022)

## PROFESSIONAL EDUCATION

- Medical Education: University of Southern California Keck School of Medicine (2004) CA
- Board Certification: Medical Oncology, American Board of Internal Medicine (2010)
- Fellowship: Stanford University Hematology and Oncology Fellowship (2010) CA
- Residency: University of California Davis (2007) CA
- Undergraduate, Harvard College (1998)

## Research & Scholarship

---

### CLINICAL TRIALS

- A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002), Not Recruiting
- A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation, Not Recruiting

## Publications

---

### PUBLICATIONS

- **Biochemical, Radiographic, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which is Best?** *Annals of surgery*  
Ahmad, M. U., Javadi, C. S., Chang, J. D., Forgó, E., Delitto, D. J., Dua, M. M., Fisher, G. A., Heestand, G. M., Chang, D. T., Pollom, E., Vitzthum, L. K., Kirane, A., Lee, et al  
2024
- **COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC.** *Future oncology (London, England)*  
Azad, N., Hu, Z., Sahin, I., Iyer, R., Aranha, O., Hochster, H., Pathak, P., Paulson, A. S., Kalyan, A., Liao, C., Tran, N., Kelley, R. K., Heestand, et al  
2024: 1-8
- **Beyond EGFR inhibitors in advanced colorectal cancer: Targeting BRAF and HER2.** *Current problems in cancer*  
Dao, V., Heestand, G.  
2023; 47 (4): 100960
- **Single-molecule methylation profiles of cell-free DNA in cancer with nanopore sequencing.** *Genome medicine*  
Lau, B. T., Almeda, A., Schauer, M., McNamara, M., Bai, X., Meng, Q., Partha, M., Grimes, S. M., Lee, H., Heestand, G. M., Ji, H. P.  
2023; 15 (1): 33
- **Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer.** *Journal of patient-reported outcomes*  
Generalova, O., Roy, M., Hall, E., Shah, S. A., Cunanan, K., Fardeen, T., Velazquez, B., Chu, G., Bruzzone, B., Cabot, A., Fisher, G. A., Srinivas, S., Fan, et al  
2021; 5 (1): 91
- **Therapeutic Monitoring of Circulating DNA Mutations in Metastatic Cancer with Personalized Digital PCR.** *The Journal of molecular diagnostics : JMD*  
Wood-Bouwens, C. M., Haslem, D. n., Moulton, B. n., Almeda, A. F., Lee, H. n., Heestand, G. M., Nadauld, L. D., Ji, H. P.  
2019
- **The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA.** *Molecular cancer therapeutics*  
Riviere, P. n., Fanta, P. T., Ikeda, S. n., Baumgartner, J. n., Heestand, G. M., Kurzrock, R. n.  
2018; 17 (1): 297–305
- **Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients.** *European journal of cancer (Oxford, England : 1990)*

Heestand, G. M., Schwaederle, M. n., Gatalica, Z. n., Arguello, D. n., Kurzrock, R. n.  
2017; 83: 80–87

- **FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.** *Journal of translational medicine*  
Shi, E., Chmielecki, J., Tang, C. M., Wang, K., Heinrich, M. C., Kang, G., Corless, C. L., Hong, D., Fero, K. E., Murphy, J. D., Fanta, P. T., Ali, S. M., De Siena, et al  
2016; 14 (1): 339
- **A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3** *PLOS ONE*  
Shultz, D. B., Pai, J., Chiu, W., Ng, K., Hellendag, M. G., Heestand, G., Chang, D. T., Tu, D., Moore, M. J., Parulekar, W. R., Koong, A. C.  
2016; 11 (1)
- **Approach to Patients With Pancreatic Cancer Without Detectable Metastases** *JOURNAL OF CLINICAL ONCOLOGY*  
Heestand, G. M., Murphy, J. D., Lowy, A. M.  
2015; 33 (16): 1770-?
- **Molecular landscape of pancreatic cancer: implications for current clinical trials** *ONCOTARGET*  
Heestand, G. M., Kurzrock, R.  
2015; 6 (7): 4553-4561
- **A novel biomarker panel examining response to gemcitabine (G) with or without erlotinib (E) for pancreatic cancer (PA) therapy in NCIC clinical trials group PA.3.**  
Shultz, D., Pal, J., Graber, M., Heestand, G. M., Chang, D., Parulekar, W. R., Tu, D., Moore, M. J., Koong, A.  
AMER SOC CLINICAL ONCOLOGY.2014
- **A novel biomarker panel examining response to adjuvant pancreatic cancer therapy in RTOG 9704**  
Heestand, G. M., Murphy, J., Moughan, J., Regine, W., Luo, J., Graber, M., Kunz, P. L., Fisher, G. A., Guha, C., Lin, B., Mowat, R. B., Gaur, R., Buyyounouski, et al  
AMER SOC CLINICAL ONCOLOGY.2014
- **Racial Disparity in Consultation, Treatment, and the Impact on Survival in Metastatic Colorectal Cancer** *JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE*  
Simpson, D. R., Martinez, M. E., Gupta, S., Hattangadi-Gluth, J., Mell, L. K., Heestand, G., Fanta, P., Ramamoorthy, S., Le, Q., Murphy, J. D.  
2013; 105 (23): 1814-1820
- **The Evolution of Modern Systemic Agents for Colorectal Cancer** *LOWER GASTROINTESTINAL MALIGNANCIES*  
Heestand, G., Kunz, P., Fisher, G. A., Ben Josef, E., Koong, A.  
2010; 1 (2): 249–60

## PRESENTATIONS

- A novel biomarker panel examining response to adjuvant pancreatic cancer therapy in RTOG 9704 - ASCO Gastrointestinal Cancers Symposium (January 17, 2014)